Should future studies suggest that the PD-1 pathway is changed in MS, molecules that can alter the levels of PD-1/PD-L1 (such as sPD-L1) may be used to regulate the immunosuppressive function of the PD-1 pathway in MS. The gene discussed is SPDL1; the disease is myeloid sarcoma.